The FDA's refusal to accept a new drug application for PTC Therapeutics Inc.'s Duchenne muscular dystrophy (DMD) candidate Translarna (ataluren) left the company pondering next steps as its shares (NASDAQ:PTCT) plunged, falling 61.6 percent, or $17.42, to close at $10.84 on Tuesday.